Related Experiment Videos

Uric Acid and Cardiovascular Events: A Mendelian Randomization Study

Marcus E Kleber1, Graciela Delgado2, Tanja B Grammer2

  • 1Fifth Department of Medicine (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany; marcus.kleber@medma.uni-heidelberg.de.

Insights

High uric acid levels are causally linked to increased cardiovascular death and sudden cardiac death. This finding highlights uric acid as a significant risk factor for heart disease in Western populations.

Area of Science:

  • Cardiovascular Research
  • Metabolic Health
  • Genetics

Background:

  • Rising prevalence of hyperuricemia, hypertension, diabetes, CKD, and cardiovascular disease in Westernized populations.
  • Obesity and diet are implicated in increased uric acid levels.
  • Need to establish a causal link between uric acid and cardiovascular risk.

Purpose of the Study:

  • To investigate if serum uric acid is an independent and causal risk factor for cardiovascular disease.
  • To examine the association between genetically predicted uric acid levels and cardiometabolic phenotypes and mortality.

Main Methods:

  • Mendelian randomization study using a genetic risk score (GRS) based on eight uric acid-regulating SNPs.
  • Serum uric acid measured in 3315 patients from the Ludwigshafen Risk and Cardiovascular Health Study.
  • Two-stage regression with GRS as instrumental variable for logistic and Cox regression analyses.

Main Results:

  • The GRS was specifically associated with uric acid levels, supporting its validity.
  • Elevated uric acid showed associations with prevalent coronary artery disease.
  • Genetically predicted uric acid was significantly associated with increased risk of cardiovascular death and sudden cardiac death.

Conclusions:

  • High serum uric acid is causally related to adverse cardiovascular outcomes.
  • Sudden cardiac death is particularly associated with elevated uric acid levels.
  • Findings suggest uric acid as a potential therapeutic target for cardiovascular disease prevention.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
129
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
17.0K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
783
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
1.2K